These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 9647243)
41. Genetic diversity of Plasmodium falciparum isolates from patients with uncomplicated and severe malaria based on msp-1 and msp-2 genes in Gublak, North West Ethiopia. Mohammed H; Hassen K; Assefa A; Mekete K; Tadesse G; Taye G; Commons RJ Malar J; 2019 Dec; 18(1):413. PubMed ID: 31823778 [TBL] [Abstract][Full Text] [Related]
43. Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-1(19)) in Iranians exposed to unstable malaria transmission. Zakeri S; Mehrizi AA; Zoghi S; Djadid ND Malar J; 2010 Sep; 9():257. PubMed ID: 20846388 [TBL] [Abstract][Full Text] [Related]
44. Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. Kang Y; Long CA Mol Biochem Parasitol; 1995 Jul; 73(1-2):103-10. PubMed ID: 8577318 [TBL] [Abstract][Full Text] [Related]
45. Variant-specific antibodies to merozoite surface protein 2 and clinical expression of Plasmodium falciparum malaria in rural Amazonians. Scopel KK; da Silva-Nunes M; Malafronte RS; Braga EM; Ferreira MU Am J Trop Med Hyg; 2007 Jun; 76(6):1084-91. PubMed ID: 17556615 [TBL] [Abstract][Full Text] [Related]
46. Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. Zhou Z; Xiao L; Branch OH; Kariuki S; Nahlen BL; Lal AA Am J Trop Med Hyg; 2002 Jan; 66(1):7-12. PubMed ID: 12135271 [TBL] [Abstract][Full Text] [Related]
47. Age-dependent antibody response to Plasmodium falciparum merozoite surface protein 2 (MSP-2). Khosravi A; Hommel M; Sayemiri K Parasite Immunol; 2011 Mar; 33(3):145-57. PubMed ID: 21306398 [TBL] [Abstract][Full Text] [Related]
48. Antibody responses to merozoite antigens after natural Plasmodium falciparum infection: kinetics and longevity in absence of re-exposure. Yman V; White MT; Asghar M; Sundling C; Sondén K; Draper SJ; Osier FHA; Färnert A BMC Med; 2019 Jan; 17(1):22. PubMed ID: 30696449 [TBL] [Abstract][Full Text] [Related]
49. Plasmodium falciparum: sequence diversity and antibody recognition of the Merozoite surface protein-2 (MSP-2) in Brazilian Amazonia. Tonon AP; Hoffmann EH; Silveira LA; Ribeiro AG; Gonçalves CR; Ribolla PE; Wunderlich G; Ferreira MU Exp Parasitol; 2004; 108(3-4):114-25. PubMed ID: 15582508 [TBL] [Abstract][Full Text] [Related]
50. Broadly reactive antibodies specific for Plasmodium falciparum MSP-1(19) are associated with the protection of naturally exposed children against infection. Dent AE; Moormann AM; Yohn CT; Kimmel RJ; Sumba PO; Vulule J; Long CA; Narum DL; Crabb BS; Kazura JW; Tisch DJ Malar J; 2012 Aug; 11():287. PubMed ID: 22909378 [TBL] [Abstract][Full Text] [Related]
51. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771 [TBL] [Abstract][Full Text] [Related]
52. Antibodies to the Plasmodium falciparum Proteins MSPDBL1 and MSPDBL2 Opsonize Merozoites, Inhibit Parasite Growth, and Predict Protection From Clinical Malaria. Chiu CY; Hodder AN; Lin CS; Hill DL; Li Wai Suen CS; Schofield L; Siba PM; Mueller I; Cowman AF; Hansen DS J Infect Dis; 2015 Aug; 212(3):406-15. PubMed ID: 25646353 [TBL] [Abstract][Full Text] [Related]
53. Epitopes in the 19kDa fragment of the Plasmodium falciparum major merozoite surface protein-1 (PfMSP-1(19)) recognized by human antibodies. Shai S; Blackman MJ; Holder AA Parasite Immunol; 1995 May; 17(5):269-75. PubMed ID: 7545808 [TBL] [Abstract][Full Text] [Related]
54. Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. Nielsen MA; Staalsoe T; Kurtzhals JA; Goka BQ; Dodoo D; Alifrangis M; Theander TG; Akanmori BD; Hviid L J Immunol; 2002 Apr; 168(7):3444-50. PubMed ID: 11907103 [TBL] [Abstract][Full Text] [Related]
55. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Polley SD; Conway DJ; Cavanagh DR; McBride JS; Lowe BS; Williams TN; Mwangi TW; Marsh K Vaccine; 2006 May; 24(19):4233-46. PubMed ID: 16111789 [TBL] [Abstract][Full Text] [Related]
56. A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission. Fonjungo PN; Elhassan IM; Cavanagh DR; Theander TG; Hviid L; Roper C; Arnot DE; McBride JS Infect Immun; 1999 Jun; 67(6):2975-85. PubMed ID: 10338508 [TBL] [Abstract][Full Text] [Related]